Condition

Mesial Temporal Lobe Epilepsy clinical trials and research

As of November 12, 2026, Find a Trial lists 3 Mesial Temporal Lobe Epilepsy clinical trials that are recruiting, in United States. By phase: Phase 3 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest Mesial Temporal Lobe Epilepsy clinical trials

StudyPhaseWhereStatusRegistered
Gene therapy for adults with refractory mesial temporal lobe epilepsy Phase 1/2 Birmingham, Alabama and 17 other locations Recruiting Oct 3, 2023
Using Deep Brain Stimulation to Preserve Memory in Epilepsy — Rochester, Minnesota and 1 other locations Recruiting Nov 8, 2022
Neural cell therapy for drug-resistant epilepsy Phase 3 Birmingham, Alabama and 35 other locations Recruiting Nov 26, 2021

All recruiting trials (3)

Quick answers

How many Mesial Temporal Lobe Epilepsy clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.